GlassScriptPhysician profile
Kelsey Murphy
NPI 1346806908
$2,616.25
in general payments reported to CMS, 2019-2025
12 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.69 · 2022: $14.56 · 2023: $234 · 2024: $1,203 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,946 · Education: $455 · Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,946.37 |
| Education | $454.87 |
| Food and Beverage | $186.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,975.21 | 2024-2025 | |
| Astellas Pharma US INC | $379.44 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $89.99 | 2024 | |
| Incyte Corporation | $30.56 | 2021-2024 | Jakafi |
| Janssen Biotech, INC. | $22.54 | 2025 | Talvey, Darzalex, Tecvayli |
| Pharmacosmos Therapeutics INC. | $19.07 | 2024 | Monoferric |
| Daiichi Sankyo INC. | $17.81 | 2025 | Datroway |
| Genmab U.S., INC. | $17.15 | 2023 | Epkinly |
| Array Biopharma INC | $16.69 | 2025 | Braftovi, Lorbrena, Mektovi |
| Abbvie INC. | $16.65 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $16.54 | 2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $14.60 | 2024 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.